Sorafenib is a multi-target kinase inhibitor that blocks cell proliferation by inhibiting the MAPK pathway, and prevents tumor-associated angiogenesis by inhibiting vascular endothelial growth factor receptors (VEGFR) as well as platelet-derived growth factor receptor (PDGFR) and FLT3 [49–51]. Here, KDR is linked to neoplasm.